FLT3-ligand administration inhibits liver metastases: Role of NK cells

Journal of Immunology

Volumn 161, Issue 11, 1998, Pages 6164-6170

  Péron, Jean Marie ^a   Esche, Clemens ^a   Subbotin, Vladimir M ^b   Maliszewski, Charles ^c   Lotze, Michael T ^a   Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELL; ENHANCER REGION; HEMATOPOIETIC CELL; IMMUNE RESPONSE; KILLER CELL; LIGAND BINDING; LIVER METASTASIS; LIVER PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL MOVEMENT; DENDRITIC CELLS; GROWTH INHIBITORS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIGANDS; LIVER NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MACROPHAGES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0032403456     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lyman, S. D., L. James, T. Vanden Bos, P. de Vries, K. Brasel, B. Gliniak, L. T. Hollingsworth, K. S. Picha, H. J. McKenna, R. R. Splett, et al. 1993. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75:1157.
2. Hannum, C., J. Culpepper, D. Campbell, T. McClanahan, S. Zurawski, J. F. Bazan, R. Kastelein, S. Hudak, J. Wagner, J. Mattson, et al. 1994. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368:643.
3. + hematopoietic progenitor cells. Blood 86:3413.
4. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1.
5. Shurin, M. R., P. P. Pandharipande, T. D. Zorina, C. Haluszczak, V. Subbotin, O. Hunter, A. Brumfield, W. J. Storkus, E. Maraskovsky, and M. T. Lotze. 1997. FLT3-Ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol. 179:174.
6. Brasel, K., H. J. McKenna, P. J. Morissey, K. Charrier, A. E. Morris, C. C. Lee, D. E. Williams, and S. D. Lyman. 1996. Hematologic effects of flt3 ligand in vivo in mice. Blood 88:2004.
7. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh. 1997. Flt3-ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3:625.
8. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
9. Germann, T., and E. Rude. 1995. Interleukin-12. Int. Arch. Allergy Immun. 108: 103.
10. Stern, A. S., J. Magram, and D. H. Presky. 1996. Interleukin-12, an integral cytokine in the immune response. Life Sci. 58:639.
11. Shurin, M. R., C. Esche, J. M. Péron, and M. T. Lotze. 1997. Antitumor activities of interleukin-12 and mechanisms of action. Chem. Immunol. 68:153.
12. Lotze, M. T., L. Zitvogel, R. Campbell, P. D. Robbins, E. M. Elder, C. Haluszczak, D. Martin, T. L. Whiteside, W. J. Storkus, and H. Tahara. 1996. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann. N.Y. Acad. Sci. 795:440.
13. Lamont, A. G., and L. Adorini. 1996. IL-12: a key cytokine in immune regulation. Immunol. Today 17:214.
14. Jacobsen, S. E. W., C. Okkenhaug, J. Myklebust, O. P. Veiby, and S. D. Lyman. 1995. The flt3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interaction with interleukin (IL)-11, IL-12 and other hematopoietic growth factors. J. Exp. Med. 181:1357.
15. Orita, K., E. Konaga, T. Okada, K. Kunisada, M. Yumura, and S. Tanaka. 1977. Effect of splenectomy in tumor-bearing mice and gastric cancer patients. Gann 68:731.
16. Jessup, J. M., N. P. Pellis, and B. D. Kahan. 1980. The spleen as a source of non-specific suppressor cells in the tumor-bearing mouse. J. Surg. Res. 28:460.
17. Meyer, J. D., B. F. Argyris, and J. A. Meyer. 1990. Splenectomy, suppressor cell activity, and survival in tumor bearing rats. J. Surg. Res. 29:527.
18. Feltkamp, M. C. W., H. L. Smits, M. P. M. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijfhout, J. ter Schegget, C. J. M. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocytes epitope-containing peptide protects against a tumor induced by human papilloma virus type 16-transformed cells. Eur. J. Immunol. 23:2242.
19. Mayordomo, J. L., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. DeLeo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
20. Celluzzi, C. M., J. L. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo. 1996. Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
21. Zitvogel, L., J. L. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, and M. T. Lotze. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
22. Hart, D. N. J., and J. W. Fabres. 1981. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med 154:347.
23. Daar, A. S., S. V. Fuggle, D. N. J. Hart, R. Dalchau, Z. Abdulaziz, J. W. Fabre, A. Ting, and P. J. Morris. 1983. Demonstration and phenotypic characterization of HLA-DR positive interstitial dendritic cells widely distributed in human connective tissues. Transplant. Proc. 15:311.
24. Woo, J., L. Lu, A. S. Rao, L. Youping, V. Subbotin, T. E. Starzl, and A. W. Thomson. 1994. Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells. Transplantation 58:484.
25. Otsuji, E., T. Yamaguchi, K. Sawai, M. Ohara, and T. Takahashi. 1996. End results of simultaneous splenectomy in patients undergoing total gastroectomy for gastric carcinoma. Surgery 120:40.
26. Shurin, M. R., E. Maraskovsky, and M. T. Lotze. 1996. FLT3-ligand inhibits tumor progression in a murine model. J. Immunother. 19:466.
27. Péron, J. M., M. R. Shurin, and M. T. Lotze. 1997. Treatment of murine subcutaneous and metastatic tumors with FLT3-ligand: a new approach in dendritic cell based immunotherapies. In: EUROCANCER-97, M. Boizon and M. Marty, eds. John Libbey Publ., Paris, p. 300.
28. Chen, K., S. Braun, S. Lyman, Y. Fan, C. M. Traycoff, E. A. Wiebke, J. Gaddy, G. Sledge, H. E. Broxmeyer, K. Cornetta. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57:3511.
29. Esche, C., V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M.R. Shurin. 1998. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58:380.
30. Lotze, M. 1997. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann. Surg. 226:1.
31. Lynch, D. 1998. Induction of dendritic cells (DC) by Flt3 ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit. Rev. Immunol. 18:99.
32. Riccardi, C., A. Santoni, T. Barlozzari, P. Puccetti, and R. B. Herberman. 1980. In vivo natural reactivity of mice against tumor cells. Int. J. Cancer 25:475.
33. Whiteside, T. L., and R. B. Herberman. 1994. Role of human natural killer cells in health and disease. Clin. Diag. Lab. Immunol. 1:125.
34. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J. Immunol. 154:4333.
35. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
36. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. III. Zeh, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic vector. J. Immunol. 154:6466.
37. Yu, W., N. Yamamoto, H. Takenaka, J. Mu, X. G. Tai, J. P. Zou, M. Ogawa, T. Tsutsui, R. Wijesuriya, R. Yoshida, et al. 1996. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int. Immunol. 8:855.
38. Bianchi, R., U. Grohmann, M. L. Belladonna, S. Silla, F. Fallarino, E. Ayroldi, M. C. Fioretti, and P. Puccetti. 1996. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol. 157:1589.
39. Shaw, S. G., A. A. Maung, R. J. Steptoe, A. W. Thomson, N. L. Vujanovic. 1998. Expansion of functional NK cells in multiple tissue compartments of mice treated with FLT3-ligand. J. Immunol. 161:2817.